Ruchi Agarwal, MD
Obstetrics & Gynecology · New York, NYNPI 1720255813
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,428 of the $50,470 with a category attached, or 82.1%. Organon accounts for 63.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $15,430 and has fallen 86.1% since, to $2,137 in 2025. Among obstetrics & gynecology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $243.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$32K
- Merck$15K
- AbbVie$899
- Avion Pharmaceuticals$279
- Exact Sciences$254
- Mayne Pharma Commercial LLC$229
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$41,42882%
- Travel & lodging$5,46611%
- Food & beverage$3,5017%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 46 | $31,884 |
| Merck | 26 | $15,281 |
| AbbVie(2 entities) | 40 | $899 |
| Avion Pharmaceuticals | 21 | $279 |
| Exact Sciences | 10 | $254 |
| Mayne Pharma Commercial LLC | 7 | $229 |
| Astellas Pharma US Inc | 5 | $171 |
| Coopersurgical, Inc. | 7 | $157 |
| Mylan Pharmaceuticals Inc. | 6 | $129 |
| Myriad Women's Health, Inc. | 1 | $126 |
| Therapeuticsmd, Inc. | 6 | $125 |
| Evofem Biosciences, Inc. | 7 | $119 |
| Shield Therapeutics Inc | 3 | $109 |
| Agile Therapeutics, Inc. | 6 | $108 |
| Ironwood Pharmaceuticals, Inc | 1 | $107 |
| Exeltis, USA Inc. | 1 | $97 |
| KCI USA, Inc. | 2 | $96 |
| Sumitomo Pharma America, Inc. | 3 | $74 |
| Myovant Sciences Inc. | 2 | $58 |
| Polarityte, Inc. | 1 | $47 |
| Pfizer | 2 | $42 |
| Scynexis, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Amgen | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,470 in reported general payments places this provider in the 95th percentile of 2,673 obstetrics & gynecology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 19 | $990 |
| Terconazole | 53 | $967 |
| ValacyclovirValacyclovir Hcl | 27 | $416 |
| Metronidazole | 11 | $316 |
| Fluconazole | 20 | $262 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $144 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $98 |
| Folic Acid | 56 | $68 |
| Misoprostol | 13 | $13 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in New York
- Mary PolanNew York$862K
- Steven GoldsteinNew York$551K
- Veronica LernerNew York$368K
- Lisa EngNew York$219K
- Rachel MaschNew York$187K
- Amy PollackNew York$184K
- Jian Qun HuangNew York$160K
- Carolyn WesthoffNew York$143K
- Melanie MarinNew York$123K
- Amitasrigowri MurthyNew York$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.